Prostate Cancer Research

Publication
Article
OncologyONCOLOGY Vol 14 No 12
Volume 14
Issue 12

A second omnibus health-care bill-this one called the Public Health Improvement Act (H.R. 2498)-was passed quietly at the end of the 2000 session, with a prostate cancer section included. That section was originally a free-standing bill called

A second omnibus health-care bill—this one called the Public Health ImprovementAct (H.R. 2498)—was passed quietly at the end of the 2000 session, with aprostate cancer section included. That section was originally a free-standingbill called the Prostate Cancer Research and Prevention Act (S. 1243). Sponsoredby Sen. Bill Frist, md (R-Tenn.), the legislation instructs the CDC toinaugurate a grant program aimed at finding out how men and their physiciansdecide whether prostate cancer screening is appropriate for them. In the future,there could be grants for screening of low-income men.

Recent Videos
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.
Ablative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Related Content